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Aims Atherosclerosis is a chronic inﬂammatory disease regulated by immune mechanisms. CD69 is a cell
surface receptor rapidly induced after leukocyte activation at sites of chronic inﬂammation. Genetic
disruption of CD69 in the mouse aggravates collagen-induced arthritis (CIA), and partial depletion of
CD69-expressing cells with anti-CD69 monoclonal antibody (mAb) prevents CIA development in wild-
type mice, suggesting that this receptor negatively modulates immune and inﬂammatory responses.
It has been recently reported that CD69 is upregulated in a large subset of T cells in atherosclerosis-
prone apolipoprotein E-null mice (apoE2/2). In this study, we investigated whether altering CD69 func-
tion affects atherosclerosis development.
Methods and results We studied native and diet-induced atherosclerosis in apoE2/2 and doubly deﬁcient
apoE2/2CD692/2 mice and performed expression studies in tissues and primary cells derived from these
animals. Plasma cholesterol level was unaffected by CD69 genetic inactivation. Although this genetic
manipulation led to an elevated production of interferon g and interleukin 10 by activated T cells,
apoE2/2 and apoE2/2CD692/2 mice fed control and high-fat diet exhibited atheromas of similar size
and composition when analysed at different stages of the disease. Likewise, anti-CD69 mAb treatment
had no effect on plasma cholesterol and atherosclerosis burden in fat-fed apoE2/2 mice.
Conclusion In contrast to previous studies highlighting the protective function of CD69 against CIA, an
autoimmune inﬂammatory disease, our results rule out a signiﬁcant role for CD69 against atherosclerosis
in apoE2/2 mice, an experimental disease model featuring a local inﬂammatory response triggered and






Atherosclerosis and the associated cardiovascular disease
(e.g. myocardial infarction, stroke, and peripheral vascular
disease) are the principal cause of morbidity and mortality
in developed countries.1 Neointimal lesion formation due
to the progressive accumulation of cellular and non-cellular
elements within the subendothelial space of the artery wall
is a hallmark of atherosclerosis. Factors contributing to
neointimal cell accumulation include the recruitment of cir-
culating leukocytes (mainly monocytes, which differentiate
into macrophages, and T cells) and excessive macrophage
and vascular smooth muscle cell (VSMC) proliferation.1–4
The activation of neointimal leukocytes triggers an inﬂam-
matory response characterized by abundant production of
cytokines and chemokines, which lead to exacerbated leu-
kocyte recruitment and proliferation and to the induction
of VSMC hyperplastic growth and migration from the tunica
media towards the growing neointimal lesion,5,6 thus contri-
buting to the progression of the disease.
A large body of evidence supports that the inﬂammatory
response associated to atherosclerosis is modulated by both
adaptive and innate immune mechanisms.7–9 Monocyte-
derived macrophages, cells of the innate immune system
which accumulate in plaques as inﬂammatory foam cells,
play an important role in the initiation and progression
of atherosclerosis.10,11 Adaptive immune system cells (e.g.
T and B lymphocytes and natural killer T cells) are also
present in atheromas, with T cells being the most abundant
inﬁltrating subset of lymphocytes.9 Although it is well
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known that murine atherosclerosis can be aggravated or atte-
nuated by different subsets of T cells, our knowledge of the
molecular mechanisms regulating the balance between pro-
and anti-atherogenic immune responses is limited.9,12
CD69 is a homodimeric leukocyte transmembrane protein
that is transiently expressed in vitro upon cell activation.13–16
Expression of CD69 is detected in small subsets of T and B
cells in peripheral lymphoid tissues.17 In addition, CD69 is
persistently expressed in the inﬁltrates of leukocytes pro-
duced during the course of chronic inﬂammatory diseases
(e.g. rheumatoid arthritis and chronic viral hepatitis)18,19
and autoimmune disorders (e.g. systemic lupus erythemato-
sus, insulin-dependent diabetes mellitus, and autoimmune
thyroiditis).20–22 Although some early in vitro ﬁndings
have suggested a proinﬂammatory function of CD69,15,23
subsequent in vivo studies showed that the development
of haematopoietic cells, the maturation of T cells, and
positive and negative selection of thymocytes are normal
in CD69-deﬁcient mice (CD692/2).24 Remarkably, these
mice show an exacerbated form of collagen-induced
arthritis (CIA) characterized by increased inﬂammation and
augmented production of proinﬂammatory cytokines [e.g.
RANTES and interleukin 1b (IL1b)] that correlate with
diminished local synthesis of transforming growth factor
b1 (TGF-b1).25 Moreover, CD692/2 mice challenged with
MHC Class Ilo tumours exhibit reduced tumour growth and
prolonged survival due to enhanced activity of natural
killer cells and reduced production of TGF-b.26 Thus, CD69
appears to be a key modulator of in vivo inﬂammatory
responses in different pathological settings.27 Further
support to this notion was provided by the observation that
systemic treatment with different anti-CD69 monoclonal anti-
bodies (mAb) can either exacerbate or inhibit the course of
CIA in the mouse.28 Moreover, the ability of the anti-CD69
mAb-2.3 to reduce inﬂammation in CIA opens the possibility
for its therapeutic use as an anti-inﬂammatory agent.
Altogether, the aforementioned results underscore CD69 as
a negative regulator of autoimmune reactivity and a putative
therapeutic target in inﬂammation. Although recent studies
using atherosclerosis-prone apolipoprotein E-null mice
(apoE2/2) have suggested that the upregulation of CD69
induces the activation of a large pool of T cells during
atheroma development,29 it remains to be established
whether CD69 expression and atherogenesis are indeed
causally linked. To address this question, we investigated
in this study the development of atherosclerosis in apoE2/2
and doubly deﬁcient apoE2/2CD692/2 mice. Moreover, we
examined the consequences of targeting CD69 with mAb-2.3
on atherosclerosis burden in apoE2/2 mice. Our results
show that neither spontaneously formed nor diet-induced
atherosclerosis is altered by in vivo targeting CD69.
2. Methods
Expanded methods are provided in Supplementary material.
2.1 Mice
The investigation conforms with the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health and was approved by the ethics review board of Consejo
Superior de Investigaciones Cientı´ﬁcas. CD692/2 mice backcrossed
12 times on a C57BL6 genetic background24 and apoE2/2 mice
(C57BL6/J, Charles River) were mated. The resulting F1 was
intercrossed, and F2 apoE2/2 and apoE2/2CD692/2 mice were
crossed to generate the two experimental groups (apoE2/2 and
apoE2/2CD692/2). Genotyping was done by PCR (see sequence of
primers in online supplement).
All studies were carried out with males. Spontaneous athero-
sclerosis was studied in 10-month-old mice always fed a low-fat
standard rodent diet (reference 2014, Teklad global rat/mouse
chow, Harlan Interfauna). When stated, 3-month-old mice were
switched for the indicated time to a high-fat diet containing
0.75% cholesterol (reference S8492-E010, Ssniff). Four
apoE2/2CD692/2 and two apoE2/2 mice died during fat feeding.
Blood was withdrawn from the retroorbital plexus to measure
plasma cholesterol level using a liquid stable reagent (WAKO).
Cholesterol bound to high-density lipoprotein (HDL-c) and to
non-HDL (non-HDL-c) were quantiﬁed with the same reagent after
precipitation with Dextran-sulphate MgCl2 (SIGMA) as described.
30
2.2 Anti-CD69 monoclonal antibody therapy
Three groups of 2-month-old male apoE2/2 mice were used. The
control group consisted of mice fed with the standard diet throughout
the study. Mice of the therapy groups were injected 300 mg of anti-
body (intraperitoneally, once per week) and switched to an athero-
genic diet for 3 weeks. Antibody injections were repeated once per
week during the 3-week period of fat feeding. The ﬁrst therapy
group was injected with the anti-mouse CD69 mAb-2.3 (mouse
IgG2a)28 and the second therapy group received mouse IgG2a
anti-human CD4 mAb HP 2/6 as isotype-matched control (IMC).
2.3 Atherosclerosis studies
Mice were euthanized and their aortas were washed in situ with PBS
and ﬁxed with freshly prepared 4% paraformaldehyde/PBS. The
heart and aorta were extracted, and ﬁxation continued for
22–28 h at 48C. Atherosclerosis was quantiﬁed by computer-assisted
planimetry of whole-mounted aortae stained with Oil Red O (0.2% in
80% MeOH, SIGMA) or cross-sections stained with haematoxylin–
eosin essentially as described.31,32 Brieﬂy, 3-mm cross-sections
were obtained from two to three different zones within the aortic
root region and the ascending aorta. In both regions, the extent
of atherosclerosis was quantiﬁed as the surface of lesion. In cross-
sections of the ascending aorta, atherosclerosis was also quantiﬁed
as the intima-to-media ratio (surface area of the intimal lesion
divided by the surface area of the media). For each mouse, the
values obtained in the different sections analysed were averaged.
Images were captured with an Olympus CAMEDIA-C5060 wide zoom
digital camera mounted on a Zeiss-Axiolab stereomicroscope. The
Sigma Scan Pro v5.0 software (Jandel Scientiﬁc) was used to quan-
tify atherosclerosis burden by an investigator who was blinded to
genotype. Methods for the immunohistopathological characteriz-
ation of atheromas are in Supplementary Material.
2.4 Statistical analysis
Results are reported as mean+SEM. For comparisons between two
groups, differences were evaluated using a two-tail, unpaired
t-test. For more than two groups, differences were evaluated using
ANOVA and post-hoc Fisher’s PLSD test (Statview, SAS Institute).
Differences were considered statistically signiﬁcant at P  0.05.
3. Results
3.1 Genetic ablation of CD69 has no effect on
diet-induced and spontaneous atherosclerosis
in apolipoprotein E-null mice
The apoE2/2 mouse spontaneously develops hypercholestero-
laemia and complex atherosclerotic lesions, two processes
that can be accelerated by a high-fat cholesterol-rich diet.33
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We ﬁrst explored the role of CD69 on diet-induced
atherosclerosis by examining 3-month-old apoE2/2 and
apoE2/2CD692/2 mice which had been challenged with an
atherogenic diet for the last 7 weeks prior to sacriﬁce.
Pre-diet plasmatic levels of total cholesterol were similar
in both groups of mice (apoE2/2: 267+20 mg/dL,
apoE2/2CD692/2: 381+16 mg/dL, P. 0.05) (Figure 1A).
As expected, fat feeding signiﬁcantly elevated plasmatic
cholesterol levels but no statistically signiﬁcant differences
were detected between apoE2/2 and apoE2/2CD692/2
mice (1340+62 and 1304+60 mg/dL, respectively; both
P, 0.0001 vs. pre-diet) (Figure 1A). In concordance with
previous studies in the apoE2/2 mouse model, the increase
in plasma cholesterol induced by fat feeding was mainly
contributed by non-HDL-c, which was similar in both groups
of mice (apoE2/2: 1316+62 mg/dL, apoE2/2CD692/2:
1272+59 mg/dL; both P, 0.0001 vs. pre-diet) (Figure 1A).
We also found no effect of CD69 disruption on atherosclerosis
burden within the aortic arch and thoracic aorta, as assessed
by Oil Red O staining of whole-mounted vessels (Figure 2A).
Consistent with these ﬁndings, analysis of the intima-to-media
ratio and total lesional surface in cross-sections from the
ascending aorta (Figure 2C) and aortic root (Figure 2E)
revealed similar extent of atherosclerosis when comparing
apoE2/2 and apoE2/2CD692/2 mice challenged with the
atherogenic diet for 7 weeks. Moreover, atherosclerosis
burden was not affected by CD69 deletion in apoE2/2 mice
fed atherogenic diet for 2 weeks, which developed compara-
tively smaller aortic atheromas (see Supplementary material
online, Figure S1).
It was feasible that a possible subtle effect of CD69 disrup-
tion on atherosclerosis might have been masked under highly
atherogenic conditions, as occurring in severely hypercholes-
terolaemic fat-fed apoE2/2 mice. However, 10-month-old
apoE2/2 and apoE2/2CD692/2 mice fed standard chow,
which exhibited plasmatic total cholesterol ,400 mg/dL
(Figure 1B), developed atheromas of similar size within the
aortic arch and thoracic aorta (Figure 2B), ascending aorta
(Figure 2D), and aortic root region (Figure 2F). Immunohisto-
pathological examination of atherosclerotic lesions revealed
undistinguishable neointimal accumulation of Mac-3-
immunoreactive macrophages, SMa-actin-immunoreactive
VSMCs, CD4-immunoreactive T cells, and collagen when
comparing apoE2/2 and apoE2/2CD692/2 mice fed either
standard chow (Figure 3A) or atherogenic diet (Figure 3B).
Collectively, these studies demonstrate that both the size
and composition of spontaneously formed and diet-induced
aortic atheromas are unaffected by genetic disruption of
CD69 in apoE2/2 mice when analysed at different stages
of the disease.
Next, we studied the production of effector cytokines
by activated T lymphocytes from apoE2/2 and
apoE2/2CD692/2 mice. Secreted cytokines were analysed
by ELISA in the supernatant of cultured splenic cells which
were activated in vitro with mAb anti-CD3. These studies
revealed elevated levels of both the proinﬂammatory
Th1-type cytokine interferon g (IFN-g) and the immunosup-
pressive cytokine IL10 in apoE2/2CD692/2 compared with
apoE2/2 cells, with the Th2-type cytokine IL4 being unaf-
fected by CD69 ablation (Figure 4A). Thus, despite the
lack of effect on atheroma formation, CD69 genetic inacti-
vation in apoE2/2 mice affects at least some aspects of
the immune reactivity of T lymphocytes. We also investi-
gated by quantitative real-time RT–PCR (qPCR) the
expression of CD25, MHC class II, and the chemokine recep-
tors CCR7 and CXCR4 in the spleen of mice fed control diet
(Figure 4B) or challenged for 6 weeks with the atherogenic
diet (Figure 4C). The results of these studies did not
reveal statistically signiﬁcant differences between groups,
thus suggesting that a compensatory upregulation of leuko-
cyte activation molecules in fat-fed apoE2/2CD692/2
mice is unlikely to account for the lack of effect of CD69
inactivation on atheroma development.
As macrophages play an important role in the initiation and
progression of atherosclerosis and upregulate CD69 upon acti-
vation,34 we assessed whether CD69 ablation affects the
inﬂammatory state of macrophages. To this end, we analysed
by qPCR the expression of the proinﬂammatory cytokines
tumor necrosis factor a (TNF-a) and IFN-g in peritoneal
macrophages harvested from mice fed control diet. As
shown in Figure 4D, both cytokines were expressed at
similar levels in apoE2/2 and apoE2/2CD692/2 mice.
3.2 In vivo treatment with the depleting anti-CD69
monoclonal antibody-2.3 has no effect on
atherosclerosis burden in apolipoprotein
E-null mice
We previously showed that CD69 targeting by mAbs affects the
course of CIA in the mouse.28 In particular, treatment with
Figure 1 Plasmatic cholesterol level in apoE-null mice is unaffected by CD69 inactivation. Quantiﬁcation of plasmatic levels of total cholesterol,
HDL-cholesterol (HDL-c), and non-HDL-c in (A) mice fed atherogenic diet for 7 weeks (n ¼ 7 mice each genotype; pre- and post-diet values) and (B) mice fed
control chow (n ¼ 4 mice each group). *, P , 0.0001 vs. pre-diet, same genotype.
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anti-CD69 mAb-2.3 reduced the severity of CIA by partially
depleting CD69-expressing effector cells. To investigate
whether this mAb also protects against atherosclerosis, we
studied three groups of apoE2/2 mice: untreated group fed
control diet, and fat-fed mice which were treated with
either anti-CD69 mAb-2.3 or with mAb-IMC (intraperitoneal
administration, once per week during the 3-week period of
fat feeding). We ﬁrst performed ﬂow cytometric analysis of
Figure 2 CD69 genetic disruption has no effect on atherosclerosis burden. Atherosclerotic lesion size was quantiﬁed in mice fed atherogenic diet for 7 weeks (A,
C, and E) or control diet (B, D, and F). (A and B) Atherosclerosis quantiﬁed in Oil Red O-stained aorta as percentage of surface occupied by lesion (red staining).
Representative images are shown. The discontinuous line marks the separation between the aortic arch and thoracic aorta. (C and D) Atherosclerosis quantiﬁed as
the intima-to-media ratio and lesional surface in haematoxylin/eosin-stained cross-sections obtained from three independent zones of the ascending aorta region
adjacent to the aortic valves. (E and F) Atherosclerosis quantiﬁed as lesional surface in haematoxylin/eosin-stained cross-sections obtained from three indepen-
dent zones from the aortic root. For each mouse, the values obtained in the different cross-sections analysed were averaged.
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thymocytes isolated from mAb-treated groups and stained
ex vivo with an anti-CD69 mAb different from 2.3. As shown
in Figure 5A, in vivo treatment with mAb-2.3 greatly
reduced CD69 expression in thymocytes when compared
with cells from mice treated with control mAb-IMC, thus con-
ﬁrming that mAb-2.3 binds in vivo to CD69-expressing cells.
We also examined the production of effector cytokines by
splenic cells activated in vitro with anti-CD3 mAb
(Figure 5B). These experiments disclosed no statistically sig-
niﬁcant differences in the production of IFN-g, IL4 and IL10
when comparing the treatments with mAb-2.3 and mAb-IMC.
Compared with basal levels in untreated mice fed control
diet, plasmatic total cholesterol was similarly elevated
in both groups of fat-fed mAb-treated mice (Figure 6A,
both P, 0.0001 vs. control diet). Likewise, atherosclerosis
burden was similar in mAb-2.3- and mAb-IMC-treated
mice, as revealed by Oil Red O staining of the aortic arch
and thoracic aorta (Figure 6B) and quantiﬁcation of the
intima-to-media ratio and total lesion size in cross-sections
through the ascending aorta (Figure 6C). Moreover, the
area occupied by neointimal macrophages in atheromas from
the aortic root was similarly increased in both groups of
Figure 3 CD69 genetic disruption has no effect on the composition of spontaneously formed and diet-induced atheromas. Aortic cross-sections were obtained
from mice fed control chow (A) or challenged with atherogenic diet for 6–7 weeks (B). Neointimal macrophages, vascular smooth muscle cells, and T-cells were
identiﬁed using anti-Mac-3, anti-SMa-actin, and anti-CD4 antibodies, respectively. Neointimal collagen content was quantiﬁed by Massson’s Trichrome staining.
Tissue was embedded in parafﬁn (anti-Mac-3, anti- SMa-actin and collagen, control chow, or atherogenic diet for 7 weeks) or Cryoblock (anti-CD4, atherogenic
diet for 6 weeks). In the confocal microscopy studies to detect CD4-immunoreactive cells (green signal), nuclei were counterstained with Topro-3 (red signal).
Representative images are shown.
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chow (Figure 6D). Taken together, these studies demonstrate
that treatment with the anti-CD69 mAb-2.3 has no effect on
the extent of atherosclerosis in fat-fed apoE2/2 mice.
4. Discussion
Atherosclerosis is a chronic inﬂammatory disease modulated
by both adaptive and innate immune mechanisms.7,8 It is
well known that different subsets of T cells can exacerbate
or attenuate murine atherosclerosis;7–9,12 therefore,
understanding the molecular mechanisms that regulate
the balance between pro- and anti-atherogenic immune
responses is of major importance. We have previously
shown that CD692/2 mice display an exacerbated form
of CIA, suggesting that CD69 is a negative regulator of
inﬂammatory responses.25,27 Notably, the percentage of
lymphocytes expressing both CD69 and CD3 is two to three
times higher in apoE2/2 mice when compared with wild-
type controls, suggesting that atherosclerosis may activate
a large pool of T cells through CD69 upregulation.29 This
could also be true for monocytes/macrophages, although
expression of CD69 in these cells has not been characterized
in the context of atherosclerosis. Importantly, dietary
factors seem to modulate the immune response associated
to atherogenesis. For example, the absence of T and B
cells had no effect on the extent of atherosclerosis
in apoE2/2 mice fed for 12 weeks a fat- and
cholesterol-enriched diet, but decreased atherosclerosis
burden in apoE2/2 mice fed standard chow.35,36 Therefore,
Figure 4 Effect of CD69 ablation on cytokine production by activated splenic T cells and peritoneal macrophages and on the expression of activation molecules
in spleen. (A) Splenocytes obtained from mice fed atherogenic diet for 7 weeks were resuspended in RPMI-1640 medium and activated in vitro with anti-CD3
antibody (20 mg/mL). After 48 h, supernatants were collected for ELISA quantiﬁcation of IFN-g, IL4, and IL10. (B–D) Quantitative real-time RT–PCR of RNA iso-
lated from spleen of mice fed control diet or challenged for 6 weeks with atherogenic diet, and from peritoneal macrophages of mice fed control diet. Results are
normalized with GAPDH (AU, arbitrary units).
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in this study, we have examined atherosclerotic lesion for-
mation in apoE2/2CD692/2 doubly deﬁcient mice and in
apoE2/2 controls receiving either control chow or a
high-fat diet to investigate the role of CD69 on both spon-
taneous and diet-induced atherosclerosis, respectively. In
both experimental settings, neither atherosclerosis burden
nor lesion composition was altered by CD69 disruption. Of
note in this regard, previous analysis of CD692/2 mice did
not reveal differences in the phenotype of lymphocyte popu-
lations or in the expression of activation markers such as
CD25 and CD4424 (and unpublished results). In the present
study, we found that the mRNA level of CD25, MHC class II,
and chemokine receptors CCR7 and CXCR4 is not signiﬁcantly
altered in the spleen of apoE2/2CD692/2 mice fed either
control or atherogenic diet (Figure 4B and C), suggesting
that the lack of effect of CD69 ablation on atherosclerosis
is not due to a compensatory upregulation of other immuno-
modulators. Moreover, expression of the proinﬂammatory
cytokines IFN-g and TNF-a in peritoneal macrophages har-
vested from apoE2/2 mice fed control diet is not affected
by CD69 deﬁciency, suggesting that CD69 is not an important
player of macrophage activation in this disease model.
Taking together, our results demonstrate that CD69
deﬁciency does not affect the course of spontaneous and
diet-induced atherosclerosis.
In the CIAmodel, inﬂammation is triggered by immunization
of mice with type II collagen, which generates T- and B-cell
responses to collagen that are crucial for disease develop-
ment.37 Indeed, the aggravation of CIA in CD692/2mice immu-
nized with collagen is associated with exacerbated responses
of T and B cells and enhanced inﬂammation.25 Recently, an
effect of CD69 on the differentiation of T lymphocytes to
effector cells has been proposed as one of the putative
mechanisms responsible for its negative regulatory effect
on inﬂammation during CIA.28 T cells also play crucial
roles on atherosclerosis by controlling inﬂammatory res-
ponses through the production of a plethora of regulatory
cytokines.7–9,12 Of particular relevance for the results
reported herein, studies using genetically modiﬁed mice
have shown that IFN-g exerts proatherogenic actions,38
whereas IL10 expression protects from atherosclerosis.39,40
We found similar number of inﬁltrating lymphocytes in athero-
sclerotic lesions of fat-fed apoE2/2 and apoE2/2CD692/2
mice (Figure 3B), but secretion of both IFN-g and IL10 was
signiﬁcantly elevated in T cells that were isolated from
fat-fed apoE2/2CD692/2 and stimulated ex vivo through
their T-cell receptor, when compared with apoE2/2 control
cells (Figure 4A). These results suggest that genetic ablation
of CD69 in the mouse increases the immune reactivity of T
cells in a manner that leads to the combined upregulation
of proatherogenic (e.g. IFN-g) and antiatherogenic
(e.g. IL10) factors, thus providing a potential mechanism
contributing to comparable atherosclerosis development in
apoE2/2CD692/2 and apoE2/2 mice. It is also noteworthy
that T and B cells have been proposed to play a minor role in
atherosclerosis in fat-fed apoE2/2 mice,35,36 suggesting
another possible explanation for the lack of effect of CD69
ablation on disease progression under highly atherogenic con-
ditions. Therefore, although our results suggest that CD69 may
play a role in the regulation of T-cell differentiation in vivo, as
previously proposed,27 additional studies in other well-
dissected experimental systems of T-lymphocyte effector
differentiation are needed to clarify this point (e.g. antigen-
dependent differentiation of lymphocytes from T-cell receptor
transgenic mice deﬁcient for CD69).
Our previous studies in the murine CIA model showed that
anti-CD69 mAb-2.3 administration can partially deplete
CD69-expressing activated effector T cells, including IFN-gþ
CD4þ lymphocytes, a response which was accompanied by a
signiﬁcant reduction in both macroscopic inﬂammation and
the production of proinﬂammatory cytokines, and by an
amelioration of disease progression.28 Thus, targeting
in vivo CD69-expressing leukocytes by treating with
mAb-2.3 might be proposed as a suitable therapeutic
agent against inﬂammatory processes. In the present work,
we examined atherosclerosis development in apoE2/2
mice treated with mAb-2.3 once per week during a 3-week
period of fat feeding. Consistent with our previous
ﬁndings,28 we observed that mAb-2.3 bound in vivo to
CD69-immunoreactive cells, as CD69 expression was reduced
in ex vivo stained thymocytes isolated from mAb-2.3- com-
pared with mAb-IMC-treated mice (Figure 5A). However,
mAb-2.3 did not alter in splenic cells the production of
cytokines known to affect atherosclerosis development
(e.g. IFN-g, IL4, and IL10) (Figure 5B), and failed to exert
any signiﬁcant effect on atheroma formation and neointi-
mal macrophage accumulation in fat-fed apoE2/2 mice
(Figure 6). These ﬁndings suggest that mAb-2.3 treatment
in apoE2/2 mice does not signiﬁcantly deplete effector T
cells, either because exhaustion of these cells is not taking
place or the effect is too subtle to alter disease progression.
The latter might be the consequence of a relatively low
upregulation of CD69 and mild level of T-cell activation
Figure 5 Anti-CD69 monoclonal antibody-2.3 (mAb-2.3) binds in vivo to
CD69-expressing cells but has no effect on cytokine production by splenic T
cells. Apolipoprotein E-null mice were treated with either anti-CD69
mAb-2.3 or mAb-isotype-matched control (IMC) (intraperitoneally, once per
week) during a 3-week period of fat feeding. (A) Percentage of
CD69-expressing cells in total thymocytes determined by ﬂow cytometry
(n ¼ 4 mice per group). The histograms show representative examples and
the graph shows the average percentage of CD69þ cells. Note that
mAb-2.3 binds in vivo to CD69-expressing thymocytes compared with
mAb-IMC. (B) Splenocytes were activated in vitro with anti-CD3 antibody
and culture supernatants were collected for ELISA quantiﬁcation of IFN-g,
IL4 and IL10.
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locally generated in response to antigens present within the
plaques of apoE2/2 mice. In contrast, the degree of T-cell
activation and the level of CD69 expression in mice immunized
with collagen plus complete Freund’s adjuvant to induce CIA
is expected to be comparatively much higher, thus favouring
the depleting effect of mAb-2.3 and the inhibitory effect on
inﬂammation observed in this model. Although additional
studies are required to clarify this important point, our ﬁnd-
ings seem to rule out the use of mAb-2.3 as a therapy
against atherosclerosis.
In summary, contrary to previous studies that highlight
a protective role of CD69 against CIA, an autoimmune
inﬂammatory disease, we have shown here that CD69
genetic ablation does not affect the size and composition
of aortic atherosclerotic lesions in the apoE2/2 mouse, an
experimental model in which local inﬂammation within the
artery wall is triggered and sustained by alterations in
lipid homeostasis. Moreover, in contrast to the beneﬁcial
effect of anti-CD69 mAb-2.3 against CIA, administration of
this antibody does not attenuate atherosclerosis develop-
ment in apoE2/2 mice. We therefore conclude that CD69
is not a good therapeutic target in the setting of
atherosclerosis.
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